We studied the scientific literature and disease guidelines in order to summarize the clinical utility of genetic testing for achromatopsia. The disease has autosomal recessive inheritance, a prevalence of 1/30000-1/50000, and is caused by mutations in the CNGB3, CNGA3, GNAT2, PDE6C, ATF6 and PDE6H genes. Clinical diagnosis is by ophthalmological examination, color vision testing and electrophysiological testing. Genetic testing is useful for confirming diagnosis and for differential diagnosis, couple risk assessment and access to clinical trials.
General information about the disease
Achromatopsia (acronym ACHM) is a rare congenital disorder characterized by reduced visual acuity (<0.2), pendular nystagmus, eccentric fixation, increased sensitivity to light (photophobia), a small central scotoma, reduced or complete loss of color discrimination and absence of cone-mediated electroretinographic amplitudes (2, 3) . Most individuals have complete ACHM, affecting the function of all three types of cones. Incomplete ACHM is much less frequent and has similar but generally less severe symptoms.
The estimated prevalence of ACHM is 1/30,000 (4). The diagnosis of ACHM is based on ophthalmological examination, testing of color vision and electroretinography (ERG), which shows loss of photopic but normal scotopic response. Optical coherence tomography shows progressive disruption and/or loss of the inner/outer segment junction of photoreceptors and attenuation of retinal pigmented epithelium (RPE) in the macular region. The diagnosis is confirmed by molecular genetic analysis of the responsible genes.
Differential diagnosis should consider blue cone monochromatism (BCM), Leber congenital amaurosis, other cone dystrophies, hereditary red-green color vision defects, yellow-blue defects and cerebral ACHM.
ACHM is a heterogeneous disorder with autosomal recessive inheritance. (5, 6) . CNGA3 and CNGB3 are the major causative genes of ACHM, and account for ~20-30% and 40-50% of the cases, respectively (6,7).
Pathogenic variants may include small intragenic deletions/ insertions, splice site variants, missense and nonsense variations; typically, exon or whole-gene duplications/deletions are not detected.
Aims of the test
• To determine the gene defect responsible for the pathology;
• To confirm clinical diagnosis of the disease;
• To determine carrier status for the disease.
Test characteristics Experts centers/Published guidelines
This test is found in the Orphanet database and is offered by 58 accredited medical genetic laboratories in the EU, and in the GTR database, offered by 10 accredited medical genetic laboratories in the US.
The guidelines for clinical use of this test are described in "Clinical utility gene card" (1) and "Gene reviews" (8) .
Test strategy
A multi-gene NGS panel is used for the detection of nucleotide variations in coding exons and flanking introns in ATF6, CNGA3, CNGB3, GNAT2, PDE6C, and PDE6H genes. Potentially causative variants and regions with low coverage are Sanger-sequenced. Sanger sequencing is also used for family segregation studies.
The test identifies variations in known causative genes in patients suspected to have ACHM. To perform molecular diagnosis, a single sample of biological material is normally sufficient. This may be 1 ml blood in a sterile tube with 0.5 ml K3EDTA or 1 ml saliva in a sterile tube with 0.5 ml ethanol 95%. Sampling rarely has to be repeated. Gene-disease associations and the interpretation of genetic variants are rapidly developing fields. It is therefore possible that genes mentioned in this note may change as new scientific data is acquired. It is also possible that genetic variants today defined as of "unknown or uncertain significance" may acquire clinical importance.
Genetic test results

Positive
Identification of biallelic pathogenic variants in CNGB3, CNGA3, GNAT2, PDE6C, ATF6 or PDE6H genes confirms the clinical diagnosis and is an indication for family studies. A pathogenic variant is known to be causative for a given genetic disorder based on previous reports or predicted to be causative based on the loss of protein function or expected significant damage to protein or protein/protein interactions. In this way it is possible to obtain a molecular diagnosis in new/other subjects, establish the risk of recurrence in family members and plan preventive and/or therapeutic measures.
Inconclusive
Detection of a variant of unknown or uncertain significance: a new variation and/or without any evident pathogenic significance or with insufficient or significant conflicting evidence to indicate it is likely benign or likely pathogenic for a given genetic disorder. In these cases, it is advisable to extend testing to the patient's relatives in order to assess variant segregation and clarify its contribution. In some cases it could be necessary to perform further examinations/tests or to do a clinical reassessment of pathological signs.
Negative
The absence of variations in the genomic regions investigated does not exclude a clinical diagnosis but suggests the possibility of:
• alterations that cannot be identified by sequencing, such as large rearrangements that cause loss (deletion) or gain (duplication) of extended gene fragments; • sequence variations in gene regions not investigated by the test, such as regulatory regions (5' and 3' UTR) and deep intronic regions; • variations in other genes not investigated by the present test.
Unexpected
Unexpected results may come out from the test, for example information regarding consanguinity, absence of family correlation or the possibility of developing genetically based diseases.
Risk for progeny
Autosomal recessive transmission needs that both healthy carrier parents transmit their disease variant to his/her children. In this case, the probability of having an affected boy or girl is therefore 25%.
Limits of the test
The test is limited by current scientific knowledge regarding the genes and disease. 
Prescription appropriateness
The genetic test is appropriate when: a) the patient meets the diagnostic criteria for achromatopsia b) the genetic test has diagnostic sensitivity greater than or equal to other published tests (≥75% of positive tests) (1) .
Clinical utility
Clinical management Utility
Confirmation of clinical diagnosis yes
Differential diagnosis yes
Access to clinical trial (10) yes
Couple risk assessment yes
